SGLT2i vs placebo
Worsening kidney function · CVD (ASCVD, HF, or both)
SGLT2i probably leads to lower worsening renal function compared with placebo (moderate certainty).
1 finding from 1 review
- Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes onlyOR 0.59 [0.43, 0.82]2 studies · 8474 participantsModerate